Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 630 W Germantown Pike, Suite 215 PLYMOUTH MEETING PA 19462 |
Tel: | N/A |
Website: | https://www.harmonybiosciences.com |
IR: | See website |
Key People | ||
Jeffrey M. Dayno President, Chief Executive Officer, Director | Sandip S. Kapadia Chief Financial Officer, Chief Administrative Officer | Jeffrey Dierks Chief Commercial Officer | Andrew Serafin Chief Strategy Officer |
Business Overview |
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. |
Financial Overview |
For the three months ended 31 March 2024, Harmony Biosciences Holdings Inc revenues increased 30% to $154.6M. Net income increased 30% to $38.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from $0.49 to $0.68. |
Employees: | 246 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,611M as of Mar 31, 2024 |
Annual revenue (TTM): | $617.51M as of Mar 31, 2024 |
EBITDA (TTM): | $228.06M as of Mar 31, 2024 |
Net annual income (TTM): | $137.70M as of Mar 31, 2024 |
Free cash flow (TTM): | $207.65M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 56,791,861 as of Apr 26, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |